BC Platforms Announces Appointment of New Chairman, Alex Dickinson
July 03 2024 - 8:00AM
BC Platforms, a global leader in real world data, healthcare data
management, and analytics, today announces the appointment of a new
Chairman of the Board.
Alex is a seasoned executive with deep
experience at the intersection of healthcare, life sciences, and
information technology. He currently sits on the boards of two
California-based companies he co-founded: Ryght (applying
generative AI to clinical trials) and Chromacode (a cloud-based
molecular diagnostics company). Alex also sits on the board of
Gencove, an NGS analytics software platform provider based in New
York. From 2017 to its acquisition in 2021 for $12B, Alex sat on
the board of PRA Health Sciences, a 20,000-employee NASDAQ-listed
Clinical Research Organization (CRO) that operated in over 80
countries.
From 2010 to 2017, Alex was SVP Strategic
Initiatives at Illumina where he led the company’s nation-scale
precision medicine program and its cloud computing efforts,
developing one of the world’s most widely used bioinformatics
platforms, BaseSpace. Alex came to Illumina through its
acquisition of Helixis, a life sciences instrument company
that he co-founded in 2007 and led as CEO.
From 2001 to 2007 he co-founded, and was CEO of,
Luxtera, a leading silicon photonics company that was later
acquired by Cisco Systems for $660M. Originally from Adelaide,
Australia, Alex has a PhD in Electrical Engineering from the
University of Adelaide, and an MBA from the Columbia Business
School in New York.
BC Platforms’ new Chairman of the Board, Alex
Dickinson, said, “I’m looking forward to driving BC Platforms’
strategic agenda, working with the remarkable team of industry
visionaries committed to making the company a global leader, and
trusted partner, in life sciences and healthcare. BC Platforms'
unique combination of a federated data network and support for
multimodal data types makes it the ideal platform to enable
insights from health data and the rapidly growing applications from
training data sets for AI-driven drug development to integration of
multiomic data into clinical workflows. BC Platforms’ proven
technology enables faster and more cost-effective drug development
and precision matching of treatments to patient needs.”
"Alex’s deep experience in M&A and his track
record as a precision medicine evangelist will reinforce and
accelerate BC Platforms’ strategy as a global technology enabler
for real world data,” said Laurent Samama who has been acting
Chairman of the Board.
Notes to Editors
About BC Platforms
BC Platforms provides its international life
sciences and healthcare clients with tools, enabling valuable
insights across the entire spectrum of research and development,
from target identification to fulfilling post-marketing
requirements. As a real world data (RWD) solutions company, powered
by its leading technology platform, the company is on a mission to
deliver personalized medicines using RWD and analytics. The
company’s acquisitions of Medexprim, in December 2023, and 4Pharma
Ltd, in June 2023, have significantly expanded its ability to
provide global biopharma partners with fast and secure access to
real world clinical and imaging data assets across Europe, as well
as new clinical research services for accelerating the translation
of innovations into clinical practice. Taken together, these
capabilities provide its customers with actionable insights to
advance precision healthcare and conduct research and development
more efficiently, thereby helping patients receive better
treatments and care.
With our innovative technology we are creating a
patient-centric infinity loop between the life sciences and
healthcare sectors. Data we generate, harmonize, and manage, from
diverse biobanks and healthcare institutions, is made accessible
for pharmaceutical and biotech companies to enhance their core
strengths in research and development. In parallel, we enable
stratification of patients towards targeted therapies, delivering
on the promise of more personalized healthcare.
Founded in 1997 from a MIT Whitehead project
spinoff, we have a strong scientific heritage underpinned by over
25 years of working in close collaboration with a network of
leading researchers, developers, and industry partners. We have
global operations with our headquarters in Zurich, Switzerland,
R&D in Espoo, Finland, and Singapore, as well as a presence in
London, UK, Lund, Sweden, Toulouse, France and Boston,
USA. For more information, visit our website and follow us on
LinkedIn.
Media Contacts
BC Platforms AG:
Mikaela Bruhammar – Interim CEOBC Platforms
AGmikaela.bruhammar@bcplatforms.com
Scius Communications:
Katja StoutTel: +44 7789 435
990katja@sciuscommunications.com
Daniel GoochTel: +44 7747 875
479daniel@sciuscommunications.com